Thermo Fisher Scientific Inc. (NYSE: TMO) has entered a definitive agreement to acquire Brammer Bio, a contract manufacturing organization (CMO) specializing in cell and gene therapies (CGT). Valued at approximately $1.7 billion in cash, the transaction represents one of the most lucrative acquisitions of a cell and gene therapy CMO to date. [Read more…]
Press Releases: Press releases are provided by the issuer and may be published by BioInformant as paid content. The issuer is solely responsible for the content and claims contained within these announcements. BioInformant does not independently verify or endorse the claims made by the issuer. For questions about an individual Press Release or to submit one, write us at [email protected].
Cellectis Secures 82,000 Sq Ft Manufacturing Facility in Raleigh to Compliment Paris Facility
Cellectis, a leading French biopharmaceutic company, has signed a lease agreement for an 82,000 sq. ft. manufacturing facility in Raleigh, North Carolina, to complement its existing 14,000 sq. ft. manufacturing facility in Paris, France.
Located at 2500 – 2540 Sumner Boulevard in Raleigh, NC, the new USA facility is owned by Equus Capital Partners and will be used for clinical and commercial production of Cellectis’ leading allogeneic UCART products.
Importantly, the decision will combine the capabilities of Cellectis’ two facilities to advance its manufacturing processes and prepare for potential commercialization of its UCART products in the future. [Read more…]
Mogrify Raises $3.7M for Direct Cell Reprogramming and Appoints Dr. Disley CEO
Mogrify (Cell Mogrify Ltd) is a private biotechnology company has developed a direct cellular conversion technology to allow for the transformation (transmogrification) of any mature human cell type into any other – without going through a pluripotent stem cell- or progenitor cell-state. [Read more…]
Sana Biotechnology, Former Juno Therapeutics Execs Co-Found New Biotech
On January 4, 2019, Sana Biotechnology became the latest regenerative medicine company to enter the marketplace, founded by former Juno Therapeutics executives Hans Bishop and Steve Harr, among other all-star executives. With operations in Seattle, WA, Cambridge, MA and San Francisco, CA, the company will be focused on creating engineered cells as medicines for patients.
Based on preliminary company statements, Sana seems to be interested in reproducing the business model and the financial success that characterized Juno Therapeutics – specifically, its ability to attract top talent from across the marketplace, accumulate investor funds, and exit for a major windfall. [Read more…]
Cell and Gene Therapies (CGT): Italy at the forefront with Anemocyte, which in Miami announces the creation of an important centre of excellence and a revolutionary drone transport system
*Photo credits: NDS – Nicolich Design Studio
The new Italian industrial complex entirely dedicated to the development and production of cell and gene therapies is called EXELLULA and it will be a world centre of excellence for nonviral technologies. FLYn’ICE, on the other hand, is a project for the transport with drones of Cell and Gene Therapies (CGT) products.
- « Previous Page
- 1
- …
- 115
- 116
- 117
- 118
- 119
- …
- 146
- Next Page »